Can your genes predict heart failure after breast cancer treatment?
NCT ID NCT02610426
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines DNA from 162 breast cancer patients who received chemotherapy and either did or did not develop congestive heart failure. Researchers want to find specific gene changes that might increase the risk of heart problems after treatment. The goal is to better understand who is at risk, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eastern Cooperative Oncology Group
RECRUITINGBoston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Phone-Based navigation could boost breast cancer detection in kenya
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a sticky film shield breast cancer patients from radiation burns in tropical heat?
- Can a simpler, cheaper method for marking breast tumors work as well as ultrasound?
- Could adding chemo help older breast cancer patients live longer? a major trial investigates.